VectorBuilder and MaxCyte have announced a strategic partnership aimed at developing an innovative gene delivery solution that integrates VectorBuilder’s MiniVec plasmid system with MaxCyte’s Flow Electroporation® technology for ex vivo cell engineering. This collaboration comes at a time when ex vivo cell therapies, including CAR-T and iPSC-based treatments, are gaining traction, yet face significant challenges related to safety and manufacturability.
Current gene delivery methods often involve trade-offs that hinder broader application; traditional electroporation can compromise cell viability, while lentiviral vectors present high production costs and safety risks. The partnership aims to address these issues by creating a next-generation electroporation-based gene delivery solution that enhances cell quality and manufacturing efficiency.
MiniVec’s design eliminates the need for antibiotic selection during fermentation, simplifying GMP-grade production, while Flow Electroporation’s continuous-flow process minimizes cellular stress, thereby improving cell viability. The combined expertise of both companies positions them to set a new standard for nonviral gene delivery, streamlining the path from research to commercialization for drug developers.
Get started today with Solo access →
